Cholesterol response of primary AML to chemotherapy
| Sample . | Untreated cells, nanomoles of cholesterol per 106 cells . | Cells treated with DNR, relative cholesterol, % . | Cells treated with ARA-C, relative cholesterol, % . |
|---|---|---|---|
| 002942 | 1.7 ± 0.1 | 140 | 190 |
| 138662 | 2.8 ± 0.0 | 110 | Not assayed |
| 141966 | 2.0 ± 0.1 | 110 | 110 |
| 149322 | 1.8 ± 0.1 | 130 | 190 |
| 151199 | 2.2 ± 0.1 | 100 | 100 |
| 151191 | 1.8 ± 0.1 | 150 | 110 |
| 152656 | 1.5 ± 0.1 | 120 | 110 |
| 153425 | 2.4 ± 0.1 | 100 | 100 |
| 153894 | 3.3 ± 0.0 | 100 | 100 |
| 154375 | 4.7 ± 0.2 | 100 | 100 |
| 154454 | 3.3 ± 0.1 | 120 | 140 |
| 155310 | 2.4 ± 0.1 | 100 | 130 |
| 155630 | 1.0 ± 0.1 | 210 | 200 |
| 155913 | 1.3 ± 0.1 | 120 | 140 |
| 156175 | 2.8 ± 0.0 | 120 | 100 |
| 158189 | 3.3 ± 0.0 | 90 | 90 |
| 158722 | 9.9 ± 0.1 | 120 | 120 |
| 165114 | 5.2 ± 0.0 | 100 | 100 |
| 47466 | 2.2 ± 0.2 | 150 | 150 |
| 47789 | 1.3 ± 0.0 | 110 | 120 |
| 48461 | 2.2 ± 0.0 | 170 | 150 |
| 49625 | 1.9 ± 0.1 | 100 | 100 |
| 51181 | 2.3 ± 0.1 | 90 | 100 |
| 51924 | 2.7 ± 0.0 | 110 | 100 |
| 55030 | 3.0 ± 0.4 | 130 | Not assayed |
| 56586 | 1.9 ± 0.0 | 130 | 120 |
| 57830 | 3.9 ± 0.2 | 100 | 100 |
| 59491 | 1.9 ± 0.0 | 120 | 130 |
| 59719 | 2.8 ± 0.0 | Not assayed | 110 |
| NBM no. 1 | 2.7 ± 0.1 | 100 | 100 |
| NBM no. 2 | 3.4 ± 0.1 | 110 | 110 |
| NBM no. 3 | 4.3 ± 0.0 | 100 | 130 |
| NBM no. 4 | 1.5 ± 0.0 | 80 | 110 |
| NBM no. 5 | 2.2 ± 0.3 | 90 | 120 |
| NBM no. 6 | 3.6 ± 0.1 | 90 | 50 |
| NBM no. 7 | 0.8 ± 0.0 | 90 | 80 |
| NBM no. 8 | 1.3 ± 0.0 | 90 | 80 |
| NBM no. 9 | 1.0 ± 0.0 | 90 | 140 |
| Sample . | Untreated cells, nanomoles of cholesterol per 106 cells . | Cells treated with DNR, relative cholesterol, % . | Cells treated with ARA-C, relative cholesterol, % . |
|---|---|---|---|
| 002942 | 1.7 ± 0.1 | 140 | 190 |
| 138662 | 2.8 ± 0.0 | 110 | Not assayed |
| 141966 | 2.0 ± 0.1 | 110 | 110 |
| 149322 | 1.8 ± 0.1 | 130 | 190 |
| 151199 | 2.2 ± 0.1 | 100 | 100 |
| 151191 | 1.8 ± 0.1 | 150 | 110 |
| 152656 | 1.5 ± 0.1 | 120 | 110 |
| 153425 | 2.4 ± 0.1 | 100 | 100 |
| 153894 | 3.3 ± 0.0 | 100 | 100 |
| 154375 | 4.7 ± 0.2 | 100 | 100 |
| 154454 | 3.3 ± 0.1 | 120 | 140 |
| 155310 | 2.4 ± 0.1 | 100 | 130 |
| 155630 | 1.0 ± 0.1 | 210 | 200 |
| 155913 | 1.3 ± 0.1 | 120 | 140 |
| 156175 | 2.8 ± 0.0 | 120 | 100 |
| 158189 | 3.3 ± 0.0 | 90 | 90 |
| 158722 | 9.9 ± 0.1 | 120 | 120 |
| 165114 | 5.2 ± 0.0 | 100 | 100 |
| 47466 | 2.2 ± 0.2 | 150 | 150 |
| 47789 | 1.3 ± 0.0 | 110 | 120 |
| 48461 | 2.2 ± 0.0 | 170 | 150 |
| 49625 | 1.9 ± 0.1 | 100 | 100 |
| 51181 | 2.3 ± 0.1 | 90 | 100 |
| 51924 | 2.7 ± 0.0 | 110 | 100 |
| 55030 | 3.0 ± 0.4 | 130 | Not assayed |
| 56586 | 1.9 ± 0.0 | 130 | 120 |
| 57830 | 3.9 ± 0.2 | 100 | 100 |
| 59491 | 1.9 ± 0.0 | 120 | 130 |
| 59719 | 2.8 ± 0.0 | Not assayed | 110 |
| NBM no. 1 | 2.7 ± 0.1 | 100 | 100 |
| NBM no. 2 | 3.4 ± 0.1 | 110 | 110 |
| NBM no. 3 | 4.3 ± 0.0 | 100 | 130 |
| NBM no. 4 | 1.5 ± 0.0 | 80 | 110 |
| NBM no. 5 | 2.2 ± 0.3 | 90 | 120 |
| NBM no. 6 | 3.6 ± 0.1 | 90 | 50 |
| NBM no. 7 | 0.8 ± 0.0 | 90 | 80 |
| NBM no. 8 | 1.3 ± 0.0 | 90 | 80 |
| NBM no. 9 | 1.0 ± 0.0 | 90 | 140 |
Primary AML cell samples (collected from 29 patients at diagnosis) and normal bone marrow cell samples (NBM, collected from 9 donors with no known disease) were treated for 24 hours with cytarabine (ARA-C; 0.04 and 0.2 μM) or daunorubicin (DNR; 0.01 and 0.05 μM) and assayed for cellular cholesterol. Similarly treated NB4 cells served as internal controls for the cholesterol assay. Constitutive cellular cholesterol data for untreated cells are expressed as nanomoles of cholesterol per 106 cells, with standard errors. Cholesterol data for DNR- or ARA-C–treated cells are expressed relative to that of the corresponding untreated cells.